Compare RUM & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RUM | DFTX |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | United States |
| Employees | 135 | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | N/A | N/A |
| Metric | RUM | DFTX |
|---|---|---|
| Price | $4.93 | $20.42 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $10.00 | ★ $40.25 |
| AVG Volume (30 Days) | 1.6M | ★ 1.6M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $209.98 | N/A |
| Revenue Next Year | $40.99 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.62 | $14.62 |
| 52 Week High | $10.99 | $21.10 |
| Indicator | RUM | DFTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.77 | 63.24 |
| Support Level | $4.67 | $16.41 |
| Resistance Level | $7.02 | N/A |
| Average True Range (ATR) | 0.23 | 1.09 |
| MACD | 0.00 | 0.23 |
| Stochastic Oscillator | 35.42 | 82.47 |
Rumble Inc is a free-to-use video-sharing platform where users can watch, share, like, comment, and upload their own videos. Users can subscribe to channels to stay in touch with recent creator content and access video-on-demand uploaded, and live content streamed, by creators. Geographically, it generates a majority of its revenue from the United States.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).